Click on image to view larger version.

Figure 4 Kaplan-Meier estimates of survival. Median survival follow-up was 15 months (range 3 to 28 months) in the entire bosentan-treated group, 15 months (range 3 to 28 months) in the bosentan subgroup without concomitant prostanoid therapy, and 16 months in the bosentan subgroup with concomitant prostanoid therapy (range 5 to 27 months).